NCT06092034Phase 2Recruiting

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Study sponsor: Rocket Pharmaceuticals Inc. · RCKT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06Estimated
Enrollment · participants18Estimated
Source updated2026-10-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Evaluation of efficacy via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index Description: Increase of myocardial tissue expression of LAMP2 protein and decrease in left ventricular mass index (LVMI). Time frame: 12 Months post-infusion. After: Measure: Evaluation of Efficacy: Improvement as assessed via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index (LVMI) Description: Myocardial tissue expression of LAMP2 protein improved from baseline to ≥ Grade 1 (by IHC), AND, ≥ 10% decrease in LVMI from baseline. Time frame: 12 months post-infusion.

Planned enrollment increased by 4 participants

Before: 14 participants (planned). After: 18 participants (planned).

Primary completion date changed

Before: Apr 2028. After: Jun 2028.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview